Famar
Athens, Greece (European operations across multiple sites)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Famar
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Athens, Greece (European operations across multiple sites)
- Modalities
- Semi-solid drug product (creams, ointments, gels), Oral solid dose, Sterile injectables, Non-sterile liquids
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Famar
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSemi-solid drug product (creams, ointments, gels), Oral solid dose, Sterile injectables, Non-sterile liquids
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (4 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (4 modalities)
Recent News 9 articles
Roche offloads Spanish production site to CMO Famar - Fierce Pharma
MidEuropa Agrees to Acquire Famar - Contract Pharma
FAMAR Group to Acquire Sterile Production Site in Homburg, Germany - Contract Pharma
On the Rise: CDMO/CMO Expansions for Injectables - DCAT Value Chain Insights
FAMAR Group Expands Its Manufacturing Footprint In Northern Europe - PA Media
Famar is changing hands once again - eKathimerini.com
MidEuropa buys majority stake in Famar from ECM, Metric Capital - pehub.com
ECM and Metric Capital to Sell a Majority Stake in FAMAR to MidEuropa - cbn.com.cy
Investment firms sell pharmaceutical company to London-based investor - Cyprus Mail
Frequently Asked Questions About Famar
What is Famar's CDMO Signal Score?
Famar has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Famar for a manufacturing program?
Use the free AI matchmaker to compare Famar against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
DPT Laboratories (Confab — Canada)
Saint-Hubert, QC, Canada
Semi-solids (creams, gels, ointments), Oral solid dose, Non-sterile liquids, Suppositories
Recipharm
Stockholm, Sweden
Semi-solid drug product (creams, ointments, gels), Sterile fill-finish, Oral solid dose, Biologics
Pierre Fabre CDMO
Toulouse, France
Pharmaceutical lozenges (hard-boiled sugar, medicated), Tablets, Capsules, Non-sterile liquids, Sterile injectables (fill-finish), APIs (botanical/synthetic), mAb/ADC (clinical batches)